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DOI 10.1016/j.immuni.2010.01.007We are pleased to read that our paper
(Sutton et al., 2009), as well as that of
Martin et al. (2009), has stimulated a
debate on the importance of gd T cells in
interleukin-17 (IL-17) production and the
signals that may drive this production.
We acknowledge the contribution that
O’Brien and colleagues have made to
our understanding of the role of IL-17
production by gd T cells in autoimmunity
in our manuscript. However, we do not
agree with their assertion that we ‘‘claim
priority’’ or that we did not acknowledge
previous contributions to the discovery
that ‘‘gd T cells can produce IL-17 without
deliberate stimulation via the T cell
receptor.’’ Indeed we cited the contribu-
tion by Shibata et al. (2007) and state in
the discussion section of our paper: ‘‘It
has also been reported that stimulation
of peritoneal exudate cells with IL-23,
but not by IL-6 and TGF-b, induced IL-
17 production by gd T cells (Shibata
et al., 2007). Our study demonstrates
a requirement for IL-1 and shows that IL-
23 and IL-1b promote innate IL-17
production from gd T cells and provides
an alternative mechanism whereby IL-23
and IL-1b may contribute to host defense
and autoimmune inflammation.’’
We did not cite the paper by Cheng et al.
(2008) because, like the data in Figure 8 of
Shibata et al. (2007), it was not based on
IL-17 production by gd T cells from naive
mice, but from mice immunized with uvei-
togenic peptide in CFA or infected with E.
coli, respectively. Therefore, as alluded to
by O’Brien et al. (2010) in their Letter, it is
possible that thesegdT cells have recently
been activated through the TCR in vivo.
The study by Shibata et al. (2007) did
examine IL-17 production by gd T cells
from naive mice (Figure 7 in their paper),
but used unpurified peritoneal exudate
cells (PECs) and showed, by intracellularcytokine staining (ICS), that 50% of gd
T cells within the PEC population secrete
IL-17 in response to in vitro stimulation
with IL-23. However, it is not possible
from this approach to conclude that IL-
23 acted directly on the gd T cells because
they did not examine IL-23R expression
on gd T cells. Furthermore, with whole
PEC populations, which include dentritic
cells (DCs) and macrophages, it is not
possible to rule out the contribution of IL-
1 or other cytokines, expressed by macro-
phages or DCs, either constitutively or in
response to TLR agonists, which
are present in many FCS preparations.
Finally, a problem with the ICS data, which
is a general problem with the vast majority
of data generated with this approach, is
that the cells were restimulated with
PMA and ionomycin after stimulation
with IL-23 and the findings need to be
confirmed with approaches that do not
require secondary stimulation in vitro.
There are a number of very important
differences from the previous work and
advances made by our study over those
reported by Shibata et al. (2007) and
by Cheng et al. (2008). Our study provides
unequivocal evidence based on cells from
gene-targeted mice, as well as in vitro
depletion and purification approaches,
with assays based on PCR, ELISA, and
ICS, that gd T cells from naive mice
express IL-17A, IL-17F, IL-21, IL-22,
IL-23R, and RORgt in response to IL-1
and IL-23 in the absence of stimulation
through the TCR. In particular, our report
(Sutton et al., 2009) together with our
earlier paper (Sutton et al., 2006) have
highlighted the importance of IL-1 and
its synergy with IL-23 in providing the
signals to promote IL-17 production by
T cells both in vitro and in vivo.
O’Brien et al. (2010) suggest that gd
T cells may require prior TCR stimulationImmunityto produce IL-17 and propose that the
responding gd T cells in our system
‘‘may have already encountered a ligand,
and would not have responded in vitro
to cytokines only were it not for that.’’
We did assess IL-17 production by gd
T cells from unimmunzed mice, in addition
to gd T cells from mice immunized with
MOG and CFA (to induce EAE). Our data
in Figure 3 clearly show that gd T cells
purified from spleens of unimmunized
mice do not secrete IL-17 or express
IL-17 mRNA in vitro in the absence of
IL-1 and IL-23 stimulation. Although we
cannot rule out a role for MTB-derived
ligands in TCR-mediated activation of gd
T cells in mice with EAE, this cannot
account for the IL-17 production we
observed in gd T cells from naive mice
after stimulation with IL-1 and IL-23
without TCR engagement. However, we
do not discount a role for stress-induced
host molecules in activation of gd T cells
in vivo. Indeed, using ICS, which involved
in vitro stimulation of the cells with PMA
and ionomycin, we did observe IL-17
production by gd T cells from lymph
nodes of naive mice, which was enhanced
when mice had been injected with IL-1
and IL-23 (Sutton et al., 2009, Figure S2B).
Therefore, it is possible that endogenous
TCR ligands may activate gd T cells
in vivo in naive mice; however, we have
no evidence to support this hypothesis.
Jensen et al. (2008) also found that a large
fraction of gd T cells from naive mice
secreted IL-17 (detected by ICS after
in vitro stimulation with anti-CD3), and
this was enhanced 3–4 days after immuni-
zation with MOG and CFA, but interest-
ingly they reported that gd T cells that
encounter ligand during development
produced IFN-g, whereas antigen-naive
gd T cells secreted IL-17. These findings
are consistent with our conclusion and,32, January 29, 2010 ª2010 Elsevier Inc. 3
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by Kapsenberg (2009), that gd T cells are
important innate source of IL-17 early in
immune responses in vivo.
O’Brien and colleagues maintain that
we ‘‘run into difficulties when they attempt
to determine which subset of gd T cells is
responding’’ and also point to confusion
in the terminology used to describe gd
T cell subsets. We accept that the termi-
nology is confusing, but this is not of our
making. It arises from the use of two inde-
pendent TCR nomenclature systems for
gd T cell subsets, that of Raulet (Garman
et al., 1986) and that of Tonegawa (Heilig
and Tonegawa, 1986). We followed the
Tonegawa nomenclature (Heilig and
Tonegawa, 1986) throughout, which is
the same as that used by O’Brien and
colleagues. There is no confusion about
Vg5 versus Vg7, the antibody we used
was specific for Vg5 (mAb clone 536).
Our rationale for testing only a selection4 Immunity 32, January 29, 2010 ª2010 Elsevof Vg and Vd subsets was partly based
on commercial availability of antibodies,
but also the need to examine a combina-
tion of gd T cell subtypes that may or
may not be expected to produce IL-17
or infiltrate the CNS. Regardless of our
rationale for choosing which subset to
study, our data clearly shows that Vg4
are a critical gd T cell subset producing
IL-17 during development of EAE.
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